The capability of Gal-3 to bind activated antigen-committed CD8+ T cells is only possible in the tumor microenvironment through Gal-3 binding to LAG-3, and thus LAG-3 expression is necessary for galectin-3-mediated suppression of CD8+ T cells in vitro. This evidence concerns the gene LAG3 and neoplasm.